Pheon Therapeutics Bolsters Board of Directors with Oncology R&D Expert Dr. Samuel Blackman
Dr. Blackman is an Entrepreneur-in-Residence at Google Ventures and a former senior pharma executive with a track record of leading the development of innovative cancer therapies
Oncology expertise spans proof-of-biology studies, biomarker development, and clinical-stage decision-making from first-in-human studies through approval
London, UK, 9 September 2025 – Pheon Therapeutics (Pheon), a clinical-stage leading Antibody-Drug Conjugate (ADC) specialist developing next-generation ADCs for a wide range of hard-to-treat cancers, today announced the appointment of accomplished oncology expert and biotech innovator, Samuel Blackman, MD, PhD, as an independent, Non-Executive Director to its Board.
